{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T22:24:57.315442+00:00","company":{"ticker":"CARM","cik":1485003,"company_name":"Carisma Therapeutics Inc."},"pagination":{"limit":100,"returned":10,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"exchange_compliance_notice","fact_key":"e4d9522e41d7543182a0261874dfae5fc41caacf","cik":1485003,"ticker":"CARM","company_name":"Carisma Therapeutics Inc.","filed_at":"2025-10-09T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"delisting_pending","cure_deadline":null,"deficiency_type":"other","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-10-09","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":[],"rules_cited_in_text":false},"claim":"Carisma Therapeutics Inc. received a nasdaq delisting notice notice regarding other.","evidence_excerpt":"October 9, 2025, Carisma Therapeutics Inc. (the “Company”)\nreceived a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”).\nThe Determination Letter indicated that, as a result of the Company’s previously disclosed noncompliance with the Nasdaq Listing\nRules, the Company’s common stock will be suspended from trading on Nasdaq effective at the open of business on October 13, 2025.\nThe Determination Letter also indicated that, after applicable appeal periods have lapsed, Nasdaq intends to file a Form 25 with the Securities\nand Exchange Commissio","confidence":0.97,"filing_url":"https://secwatch.observer/filing/0001104659-25-098404","anchor_url":"https://secwatch.observer/filing/0001104659-25-098404#claim-e4d9522e41d7543182a0261874dfae5fc41caacf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925098404/0001104659-25-098404-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"4a763a458d226c4ed60e9fee96fd019e160f0412","cik":1485003,"ticker":"CARM","company_name":"Carisma Therapeutics Inc.","filed_at":"2025-01-10T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2025-07-07","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":"$1.00","notice_date":"2025-01-06","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5450(a)(1)"]},"claim":"Carisma Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"January 6, 2025, Carisma Therapeutics Inc. (the “Company”)\nreceived written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that, based upo","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-002522","anchor_url":"https://secwatch.observer/filing/0001104659-25-002522#claim-4a763a458d226c4ed60e9fee96fd019e160f0412","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925002522/0001104659-25-002522-index.htm"},{"fact_type":"executive_change","fact_key":"04615deb54","cik":1485003,"ticker":"CARM","company_name":"Carisma Therapeutics Inc.","filed_at":"2024-10-30T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-31","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Sohanya Cheng was elected as Director at Carisma Therapeutics Inc..","evidence_excerpt":"On October 30, 2024, the Board elected Sohanya Cheng as a director of the Company, effective October 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-112629","anchor_url":"https://secwatch.observer/filing/0001104659-24-112629#claim-04615deb54","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924112629/0001104659-24-112629-index.htm"},{"fact_type":"executive_change","fact_key":"1bb7587302","cik":1485003,"ticker":"CARM","company_name":"Carisma Therapeutics Inc.","filed_at":"2024-10-30T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-10-31","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael Torok resigned as Director at Carisma Therapeutics Inc..","evidence_excerpt":"On October 24, 2024, Michael Torok notified Carisma Therapeutics Inc. (the “Company”) of his decision to resign from the Company’s board of directors (the “Board”), effective October 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-112629","anchor_url":"https://secwatch.observer/filing/0001104659-24-112629#claim-1bb7587302","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924112629/0001104659-24-112629-index.htm"},{"fact_type":"executive_change","fact_key":"dbdf99a923","cik":1485003,"ticker":"CARM","company_name":"Carisma Therapeutics Inc.","filed_at":"2024-07-01T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-30","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"David Scadden was elected as Director at Carisma Therapeutics Inc..","evidence_excerpt":"On June 26, 2024, the board of directors elected Marella Thorell and David Scadden, M.D. as directors of the Company, effective June 30, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-076578","anchor_url":"https://secwatch.observer/filing/0001104659-24-076578#claim-dbdf99a923","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924076578/0001104659-24-076578-index.htm"},{"fact_type":"executive_change","fact_key":"597f2bf1f0","cik":1485003,"ticker":"CARM","company_name":"Carisma Therapeutics Inc.","filed_at":"2024-07-01T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-30","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Marella Thorell was elected as Director at Carisma Therapeutics Inc..","evidence_excerpt":"On June 26, 2024, the board of directors elected Marella Thorell and David Scadden, M.D. as directors of the Company, effective June 30, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-076578","anchor_url":"https://secwatch.observer/filing/0001104659-24-076578#claim-597f2bf1f0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924076578/0001104659-24-076578-index.htm"},{"fact_type":"executive_change","fact_key":"56ae90ba44","cik":1485003,"ticker":"CARM","company_name":"Carisma Therapeutics Inc.","filed_at":"2024-07-01T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-06-30","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Björn Odlander resigned as Director at Carisma Therapeutics Inc..","evidence_excerpt":"On June 26, 2024, each of Regina Hodits, Ph.D. and Björn Odlander, M.D., Ph.D. notified Carisma Therapeutics Inc. (the “Company”) of their respective decisions to resign from the Company’s board of directors, effective June 30, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-076578","anchor_url":"https://secwatch.observer/filing/0001104659-24-076578#claim-56ae90ba44","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924076578/0001104659-24-076578-index.htm"},{"fact_type":"executive_change","fact_key":"0feaee61bc","cik":1485003,"ticker":"CARM","company_name":"Carisma Therapeutics Inc.","filed_at":"2024-07-01T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-06-30","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Regina Hodits resigned as Director at Carisma Therapeutics Inc..","evidence_excerpt":"On June 26, 2024, each of Regina Hodits, Ph.D. and Björn Odlander, M.D., Ph.D. notified Carisma Therapeutics Inc. (the “Company”) of their respective decisions to resign from the Company’s board of directors, effective June 30, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-076578","anchor_url":"https://secwatch.observer/filing/0001104659-24-076578#claim-0feaee61bc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924076578/0001104659-24-076578-index.htm"},{"fact_type":"earnings_release","fact_key":"54127c8f1c37d25178389f416beb645fd4a2f78f","cik":1485003,"ticker":"CARM","company_name":"Carisma Therapeutics Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":null},"claim":"Carisma Therapeutics Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, Carisma Therapeutics Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-059130","anchor_url":"https://secwatch.observer/filing/0001104659-24-059130#claim-54127c8f1c37d25178389f416beb645fd4a2f78f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924059130/0001104659-24-059130-index.htm"},{"fact_type":"earnings_release","fact_key":"84780d8f2a9854e7451ab9073c99bc135765921e","cik":1485003,"ticker":"CARM","company_name":"Carisma Therapeutics Inc.","filed_at":"2024-04-01T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fourth quarter and full year ended December 31, 2023","report_date":"2024-04-01","result_type":"reported_results","revenue_text":null},"claim":"Carisma Therapeutics Inc. reported financial results for fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On April 1, 2024, Carisma Therapeutics Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-041568","anchor_url":"https://secwatch.observer/filing/0001104659-24-041568#claim-84780d8f2a9854e7451ab9073c99bc135765921e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924041568/0001104659-24-041568-index.htm"}]}